Skip to main content
OpenTrials
Completed

NCT Number: NCT01809925

Study of Psyllium 6.8 g Versus Placebo on Satiety in Healthy Volunteers

This is a randomized, double-blind, placebo-controlled, 2-treatment, 3-period crossover design study to evaluate the effects of psyllium 6.8 g provided as sugarfree Metamucil fiber supplement powder dissolved in water versus placebo on satiety measures in healthy volunteers. This study will be conducted at a single study site.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Study Center

Cincinnati, Ohio, 45227, United States

About this study

A total of 45 subjects will be enrolled in this study. Approximately equal numbers of men and women will be enrolled, with a race distribution consistent with the US population. Eligible subjects will be randomly assigned to 1 of 2 test product sequences at Test Period 1 (Visit 2) using a block randomization. Subjects will participate in 3 test periods (Test Period 1, Visits 2-4; Test Period 2, Visits 5-7; and Test Period 3, Visits 8-10) and will receive test product once a day before breakfast for 3 days within each period. Test periods will be separated by a minimum 4-day washout period in which no test product will be administered.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects who meet all of the following criteria are eligible to participate in the study:

  • routinely eat breakfast daily;
  • agree to eat 100% of the food provided during the study, drink 10 ounces of water with the test product immediately before breakfast, and only eat a light snack after dinner before fasting overnight beginning at 10:00 PM prior to the next visit;
  • have a screening VAS Hunger score > 50 before eating breakfast that moves towards less hunger after eating breakfast;
  • have 1-2 bowel movements per day that are typically rated as 3, 4, or 5 on the Bristol Stool Form Scale;
  • in good general health based on medical history;
  • if female, be postmenopausal or if of child-bearing capacity agree to use an adequate form of contraception (eg, surgical sterilization, birth control pills, birth control implants, condoms AND spermicide, abstinence);
  • have a body mass index (BMI) ≥ 18.5 but < 28 kg/m2;
  • able to fulfill the requirements of the protocol and provide written consent;
  • willing to abstain from any weight control or satiety supplements during the study;
  • willing to refrain from taking any psyllium containing products or fiber supplements during the study with the exception of the test products;
  • willing to maintain lifestyle habits for the duration of the study (eg, do not change exercise habits or begin a weight loss diet);
  • willing to refrain from exercise on the mornings prior to arriving at the study site;
  • willing to abstain from alcohol for 2 days prior to the first day of each test period through the last day of each test period;
  • willing not to consume caffeine for 24 hours prior to the first day of each test period through the last day of each test period.

Exclusion criteria

Subjects will be excluded from the study if they meet any of the following criteria:

  • have any history of heart, liver, kidney, nerve, blood disorder, or cancer(except for treated basal cell cancer with a documented 6-month remission), or metabolic, hormone, or gastrointestinal (GI) disease;
  • have a history of an eating disorder;
  • have difficulty swallowing;
  • have a history of gastrointestinal surgery (except appendectomy) or gastrointestinal bleeding;
  • are currently alcohol or chemically dependent (a urine test for drugs of abuse will be given);
  • report use of tobacco, smoking cessation products, or products containing nicotine within 3 months;
  • have a significant psychiatric disorder;
  • any use of prescription drugs, with the exception of birth control pills, within 14 days prior to the study or antibiotics in the past 30 days;
  • any use of non-prescription drugs within 7 days prior to the study;
  • used psyllium containing products or fiber supplements within the past month;
  • have a history of phenylketonuria (PKU);
  • have a history of a severe allergic reaction to psyllium;
  • are currently on a structured formal diet (eg, Jenny Craig, Atkins);
  • typically drink more than 70 ounces of liquid during the day (ie, approximately 4 bottles of water, each 16.9 ounces)
  • have a history or presence, upon clinical evaluation, of any illness or condition that might impact the safety of the study product;
  • participated in a clinical drug study or used an investigational new drug within 30 days of dosing;
  • pregnant or nursing, if female;
  • engage in excessive exercise that is extreme in frequency or duration;
  • find the study meals unpalatable

Treatment and study plan

psyllium fiber 6.8g

Dietary Supplement

Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.

Other names: Metamucil Orange Sugar Free Fiber Singles (psyllium 6.8 g)

Placebo

Dietary Supplement

Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.

Primary outcomes

  1. satiety (VAS Hunger 3-day average)

    Time frame: Hours 0-4.5

    VAS Hunger 3-day average. This endpoint will be calculated by averaging all evaluable post-breakfast scores across Days 1, 2, and 3. VAS Hunger is assessed on a horizontal 100-mm VAS anchored on the left by the phrase "Not at all hungry" (score = 0) and on the right by "As hungry as I have ever felt" (score = 100).

Secondary outcomes

  1. Satiety Labeled Intensity Magnitude (SLIM) 3-day average

    Time frame: Hours 0-4.5

    SLIM 3-day average is calculated by averaging all evaluable post-breakfast scores across Days 1, 2, and 3. SLIM scale gauges perceived hunger/fullness following a meal using 11 phrases placed along a vertical line scale anchored at the bottom by "Greatest imaginable hunger" (score = -100) and at the top by "Greatest imaginable fullness" (score = 100).

  2. VAS Desire to Eat 3-day average

    Time frame: Hours 0-4.5

    The VAS Desire to Eat 3-day average is calculated by averaging all evaluable post-breakfast scores across Days 1, 2, and 3. The VAS Desire to Eat Scale asks subjects to rate their desire to eat using a horizontal 100-mm VAS anchored on the left by the phrase "No desire at all" (score = 0) and on the right by "As strong as I have ever felt" (score = 100)

  3. VAS Hunger 3-day average for hours 3.0 - 4.5

    Time frame: Hours 3.0 - 4.5

    The VAS Hunger 3-day average for hours 3.0 - 4.5 is calculated by averaging all evaluable post-breakfast scores for hours 3.0, 3.5, 4.0, and 4.5 across Days 1, 2, and 3. The VAS Desire to Eat Scale asks subjects to rate their desire to eat using a horizontal 100-mm VAS anchored on the left by the phrase "No desire at all" (score = 0) and on the right by "As strong as I have ever felt" (score = 100).

  4. SLIM 3-day average for Hours 3.0-4.5

    Time frame: Hours 3.0-4.5

    SLIM 3-day average for Hours 3.0-4.5 is calculated by averaging all evaluable post-breakfast scores for hours 3.0, 3.5, 4.0, and 4.5 across Days 1, 2, and 3. The SLIM scale gauges perceived hunger/fullness following a meal using 11 phrases placed along a vertical line scale anchored at the bottom by "Greatest imaginable hunger" (score = -100) and at the top by "Greatest imaginable fullness" (score = 100).

  5. VAS Desire to Eat 3-day average for hours 3.0 - 4.5

    Time frame: Hours 3.0-4.5

    The VAS Desire to Eat 3-day average for hours 3.0-4.5 is calculated by averaging all evaluable post-breakfast scores for hours 3.0, 3.5, 4.0, and 4.5 across Days 1, 2, and 3. The VAS Desire to Eat Scale asks subjects to rate their desire to eat using a horizontal 100-mm VAS anchored on the left by the phrase "No desire at all" (score = 0) and on the right by "As strong as I have ever felt" (score = 100).

Sponsors and collaborators

Lead sponsor

Procter and Gamble

Industry

Registry information

Official study title

Randomized, Double-blind, Placebo-controlled, 2-treatment, 3-period Crossover Design Study of the Efficacy and Tolerability of Psyllium 6.8 g Provided as Sugarfree Metamucil® Fiber Supplement Powder Versus Placebo on Satiety in Healthy Volunteers

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Mar 13, 2013
Registry last updated
Oct 28, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.